Barry Kenny
Corporate Officer/Principal presso Heptares Therapeutics Ltd.
Profilo
Barry Kenny is the founder of Cambridge Drug Discovery Holdings Ltd., which was founded in 1997.
He held the title of Principal from 1997 to 2013.
Currently, he is the Chief Business Officer at Heptares Therapeutics Ltd.
In the past, he worked as a Commercial Director at Paradigm Therapeutics Ltd.
from 2003 to 2007.
He was also a Director-Business Development at Biofocus, Inc. He held the position of Non-Executive Director at Metrion Biosciences Ltd.
from 2018 to 2023.
Additionally, he worked as a Principal at Syntex Research Centre and Pfizer Central Research, and as a Vice President-Drug Discovery at Takeda Cambridge Ltd.
Posizioni attive di Barry Kenny
Società | Posizione | Inizio |
---|---|---|
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Corporate Officer/Principal | 02/11/2009 |
Precedenti posizioni note di Barry Kenny
Società | Posizione | Fine |
---|---|---|
Metrion Biosciences Ltd.
Metrion Biosciences Ltd. BiotechnologyHealth Technology Metrion Biosciences Ltd. is a contract research organization that specializes in providing drug discovery services to pharmaceutical and bioscience customers. Metrion Biosciences is based in Great Abington, UK and was founded in 2015. The British company offers a range of high-quality ion channel assays on a fee-for-service or collaboration basis, including an industry-leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Andrew Southan has been the CEO of the company since 2016. | Direttore/Membro del Consiglio | 20/12/2023 |
Paradigm Therapeutics Ltd.
Paradigm Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK. | Corporate Officer/Principal | 12/03/2007 |
Biofocus, Inc.
Biofocus, Inc. Pharmaceuticals: MajorHealth Technology Biofocus, Inc. operates as a clinical biotechnology company. The company is headquartered in the United Kingdom. | Corporate Officer/Principal | - |
Syntex Research Centre
Syntex Research Centre Pharmaceuticals: OtherHealth Technology Syntex Research Centre is a British company that provides pharmaceutical products. Syntex Research Centre was acquired by Quintiles Scotland Ltd on February 01, 1995 for $20.68 million. | Corporate Officer/Principal | - |
PFIZER, INC. | Corporate Officer/Principal | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
PFIZER, INC. | Health Technology |
Aziende private | 7 |
---|---|
Paradigm Therapeutics Ltd.
Paradigm Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK. | Health Technology |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Health Technology |
Cambridge Drug Discovery Holdings Ltd.
Cambridge Drug Discovery Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Charles River Laboratories International, Inc., Cambridge Drug Discovery Holdings Ltd. is a company that researches potential new drugs for the treatment of cancer. The company is based in Cambridge, UK. Cambridge Drug Discovery Holdings was acquired by Charles River Discovery Research Services UK Ltd., part of Charles River Laboratories International, Inc. from November 14, 2005 on June 11, 2001 for $38 million. The British company was founded by Barry Kenny, Jonathan Mark Treherne. | Commercial Services |
Takeda Cambridge Ltd.
Takeda Cambridge Ltd. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Takeda Cambridge Ltd. is a company that develops and manufactures pharmaceutical products. The company is based in Cambridge, UK and was founded in 1998. | Health Technology |
Syntex Research Centre
Syntex Research Centre Pharmaceuticals: OtherHealth Technology Syntex Research Centre is a British company that provides pharmaceutical products. Syntex Research Centre was acquired by Quintiles Scotland Ltd on February 01, 1995 for $20.68 million. | Health Technology |
Biofocus, Inc.
Biofocus, Inc. Pharmaceuticals: MajorHealth Technology Biofocus, Inc. operates as a clinical biotechnology company. The company is headquartered in the United Kingdom. | Health Technology |
Metrion Biosciences Ltd.
Metrion Biosciences Ltd. BiotechnologyHealth Technology Metrion Biosciences Ltd. is a contract research organization that specializes in providing drug discovery services to pharmaceutical and bioscience customers. Metrion Biosciences is based in Great Abington, UK and was founded in 2015. The British company offers a range of high-quality ion channel assays on a fee-for-service or collaboration basis, including an industry-leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Andrew Southan has been the CEO of the company since 2016. | Health Technology |
- Borsa valori
- Insiders
- Barry Kenny